What were Supriya Lifescience Ltd's latest quarterly results?
Supriya Lifescience Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +48.0% (turning around (inflection up))
- Revenue Growth YoY: +50.5%
- Operating Margin: 35.0% (contracting)
Supriya Lifescience Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +49.0%Average4w StreakRe-Entry
In , Supriya Lifescience Ltd (Pharma - API & CRAMS) is outperforming Nifty 500 with +49.0% relative strength. Fundamentals: Average. On a 4-week streak.
Supriya Lifescience Ltd Key Facts
- PE Ratio
- 35.7x
- Market Cap
- ₹7,470 Cr
- PAT Growth YoY
- +48%
- Revenue Growth YoY
- +51%
- OPM
- 35.0%
- RS vs Nifty 500
- +49.0%
PE: At PeakEmerging Opportunity
What's Happening
⏳Steady earner with flat PE — waiting for re-rate catalyst
🏦Virtually debt-free company
🌐FII stake decreased 0.6% this quarter
💰Trading 16% above estimated fair value
Key Numbers
PAT Growth YoY
+48%
Inflection Up
Revenue YoY
+51%
Inflection Up
Operating Margin
35.0%
-200 bps YoY
PE Ratio
35.7
Current Price
₹928
Dividend Yield
0.11%
Fundamental Score
56/100
Average
3Y PAT CAGR
+32%
Market Cap
7.5K Cr
Valuation
Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Supriya Lifescience Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +51% | +22% | Inflection Up |
| PAT (Net Profit) | +48% | +32% | Inflection Up |
| OPM | 35.0% | -200 bps | Contracting |
Other Top Pharma - API & CRAMS Stocks Beating Nifty 500
Frequently Asked Questions: Supriya Lifescience Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Supriya Lifescience Ltd's profit growing or declining?
Supriya Lifescience Ltd's profit is growing with an turning around (inflection up) trend.
- PAT Growth YoY: +48.0% (latest quarter)
- PAT Growth QoQ: +48.0% (sequential)
- 3-Year PAT CAGR: +32.4%
- Trend: Turning around (inflection up) — consistent growth pattern
What is Supriya Lifescience Ltd's revenue growth trend?
Supriya Lifescience Ltd's revenue growth trend is turning around (inflection up).
- Revenue Growth YoY: +50.5%
- Revenue Growth QoQ: +34.5% (sequential)
- 3-Year Revenue CAGR: +21.6%
How is Supriya Lifescience Ltd's operating margin trending?
Supriya Lifescience Ltd's operating margin is contracting.
- Current OPM: 35.0%
- OPM Change YoY: -2.0% basis points
- OPM Change QoQ: 0.0% basis points
What is Supriya Lifescience Ltd's 3-year profit and revenue CAGR?
Supriya Lifescience Ltd's long-term compounding rates
- 3-Year Profit CAGR: +32.4%
- 3-Year Revenue CAGR: +21.6%
Is Supriya Lifescience Ltd's growth accelerating or decelerating?
Supriya Lifescience Ltd's earnings growth is turning around (inflection up) with mixed signals on a sequential basis.
- YoY Acceleration: +41.6% bps
- Sequential Acceleration: +48.0% bps
- Margin Warning: Operating margins are under pressure
What is Supriya Lifescience Ltd's trailing twelve month (TTM) performance?
Supriya Lifescience Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹209 Cr
- TTM PAT Growth: +11.2% YoY
- TTM Revenue: ₹828 Cr
- TTM Revenue Growth: +18.8% YoY
- TTM Operating Margin: 35.4%
Is Supriya Lifescience Ltd overvalued or undervalued?
Supriya Lifescience Ltd appears overvalued based on our fair value analysis.
- Valuation Signal: Overvalued
- Current PE: 35.7x
- Price-to-Book: 6.2x
What is Supriya Lifescience Ltd's current PE ratio?
Supriya Lifescience Ltd's current PE ratio is 35.7x.
- Current PE: 35.7x
- Market Cap: 7.5K Cr
- Dividend Yield: 0.11%
How does Supriya Lifescience Ltd's valuation compare to its history?
Supriya Lifescience Ltd's current PE is 35.7x.
- Current PE: 35.7x
- Valuation Assessment: Overvalued
What is Supriya Lifescience Ltd's price-to-book ratio?
Supriya Lifescience Ltd's price-to-book ratio is 6.2x.
- Price-to-Book (P/B): 6.2x
- Book Value per Share: ₹149
- Current Price: ₹928
Is Supriya Lifescience Ltd a fundamentally strong company?
Supriya Lifescience Ltd is rated Average with a fundamental score of 56/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +50.5% (10% weight)
- PAT Growth YoY: +48.0% (10% weight)
- PAT Growth QoQ: +48.0% (10% weight)
- Margins contracting (10% weight)
Is Supriya Lifescience Ltd debt free?
Supriya Lifescience Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹5 Cr
What is Supriya Lifescience Ltd's return on equity (ROE) and ROCE?
Supriya Lifescience Ltd's return ratios over recent years
- FY2024: ROCE 22.0%
- FY2025: ROCE 27.0%
- FY2026: ROCE 25.0%
Is Supriya Lifescience Ltd's cash flow positive?
Supriya Lifescience Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹165 Cr
- Free Cash Flow (FCF): ₹13 Cr
- CFO/PAT Ratio: 88% (strong cash conversion)
What is Supriya Lifescience Ltd's dividend yield?
Supriya Lifescience Ltd's current dividend yield is 0.11%.
- Dividend Yield: 0.11%
- Current Price: ₹928
Who holds Supriya Lifescience Ltd shares — promoters, FII, DII?
Supriya Lifescience Ltd's shareholding pattern (Mar 2026)
- Promoters: 68.3%
- FII (Foreign): 5.2%
- DII (Domestic): 5.7%
- Public: 20.8%
Is promoter holding increasing or decreasing in Supriya Lifescience Ltd?
Supriya Lifescience Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 68.3% (Mar 2026)
- Previous Quarter: 68.3% (Dec 2025)
- Change: 0.00% (stable)
How long has Supriya Lifescience Ltd been outperforming Nifty 500?
Supriya Lifescience Ltd has been outperforming Nifty 500 for 4 consecutive weeks, indicating building momentum.
Is Supriya Lifescience Ltd a new momentum entry or an established outperformer?
Supriya Lifescience Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
Is Supriya Lifescience Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Supriya Lifescience Ltd may be worth studying
- Earnings growing at +48.0% YoY
- Cash flow is positive — CFO ₹165 Cr
What is the investment thesis for Supriya Lifescience Ltd?
Supriya Lifescience Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +50.5% YoY
Risk Factors (Bear Case)
- Margins under pressure
- Appears overvalued
What is the future outlook for Supriya Lifescience Ltd?
Supriya Lifescience Ltd's forward outlook based on current data signals
- Earnings Trend: turning around (inflection up)
- Revenue Trend: turning around (inflection up)
- Margin Trend: contracting
- Valuation: Overvalued
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.